
mCRC beim ESMO 2020 - Panitumumab
Interimsanalyse der nicht-interventionellen Studie VALIDATE: Erstlinientherapie des RAS-Wildtyp metastasierten kolorektalen Karzinoms mit Panitumumab plus FOLFIRI oder FOLFOX (Uhlig J. et al. Abstract 457P)
Interimsanalyse der nicht-interventionellen Studie VALIDATE: Erstlinientherapie des RAS-Wildtyp metastasierten kolorektalen Karzinoms mit Panitumumab plus FOLFIRI oder FOLFOX (Uhlig J. et al. Abstract 457P)
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties